Eupraxia Pharmaceuticals (X43) Stock Overview
A clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
X43 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Eupraxia Pharmaceuticals Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$6.35 |
| 52 Week High | CA$7.40 |
| 52 Week Low | CA$3.14 |
| Beta | 1.42 |
| 1 Month Change | 3.25% |
| 3 Month Change | -5.93% |
| 1 Year Change | 89.27% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 102.52% |
Recent News & Updates
Recent updates
Shareholder Returns
| X43 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0.8% | 3.6% | 0.06% |
| 1Y | 89.3% | -11.2% | 1.0% |
Return vs Industry: X43 exceeded the German Biotechs industry which returned -11.2% over the past year.
Return vs Market: X43 exceeded the German Market which returned 1% over the past year.
Price Volatility
| X43 volatility | |
|---|---|
| X43 Average Weekly Movement | 10.0% |
| Biotechs Industry Average Movement | 8.7% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in DE Market | 12.3% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: X43's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: X43's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 49 | James Helliwell | www.eupraxiapharma.com |
Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. The company’s product portfolio includes EP-104IAR, which is in Phase III clinical trial for the treatment of knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis; and EP-104, which is under preclinical studies for the treatment of gastrointestinal tract, such as eosinophilic esophagitis.
Eupraxia Pharmaceuticals Inc. Fundamentals Summary
| X43 fundamental statistics | |
|---|---|
| Market cap | €415.07m |
| Earnings (TTM) | -€35.08m |
| Revenue (TTM) | n/a |
Is X43 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| X43 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$41.11m |
| Earnings | -US$41.11m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.67 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did X43 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/03 08:27 |
| End of Day Share Price | 2026/04/30 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Eupraxia Pharmaceuticals Inc. is covered by 9 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Martin | Bloom Burton & Co. |
| Tania Armstrong-Whitworth | Canaccord Genuity |
| Kristen Kluska | Cantor Fitzgerald & Co. |